Amgen Inc.

Teijin Pharma Limited

Benjamin Charles Milgram

Matthew M Weiss

Angel Guzman-Perez

Isaac E Marx

Alessandro Boezio

Thomas Dineen

John Stellwagen

Daniel La

John R Butler

Brian Andrew Sparling

Alan H Cherney

Wei Zhao

Ryan D White

Laurie B Schenkel

Michael D Bartberger

Russell Graceffa

Daniel B Horne

Hanh Nho Nguyen

Gwenaella Rescourio

Charles Kreiman

Erin F DiMauro

Zihao Hua

Haoxuan Wang

Nagasree Chakka

Emily Anne Peterson

Hongbing Huang

Margaret Chu-Moyer

Jane Panteleev

Christiane Boezio

Daniel C H Lin

Hua Gao

Karina R Vaida

Madeleine Kieffer

Issac E Marx

Angel Guzman-perez

The present invention provides a cyclobutyl dihydroquinoline sulfonamide compound of Formula (I), an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, that inhibits voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing the compounds of the present invention. Also further provided is an atropi-selective preparation of said compounds of Formula (I), and intermediate thereof.

Cyclobutyl dihydroquinoline sulfonamide compounds

The present invention provides a compound of Formula (I):

Cyclopropyl dihydroquinoline sulfonamide compounds

The present invention relates to inhibitors of Transient Receptor Potential Channel 6 (TRPC6) protein activity. The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof. 

Benzimidazole derivatives and their uses

The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention. 

Pyridine sulfonamides

The present invention provides compounds of Formula (I), wherein: as defined in the specification, an enantiomer, diastereomer, atropisomer thereof, or a mixture thereof, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

Bicyclic ketone sulfonamide compounds

The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention. 

Alkyl dihydroquinoline sulfonamide compounds

The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

Bicyclic sulfonamide compounds as sodium channel inhibitors

Growing community of inventors

Cambridge, MA, United States of America

Benjamin Charles Milgram